News

Blocking synuclein nitrase eases paralysis in mouse study

Blocking the activity of the synuclein nitrase enzyme reduced the levels of toxic clumps of the alpha-synuclein protein and lessened paralysis in mouse models of Parkinson’s disease, according to new data from Nitrase Therapeutics. Formation of toxic aggregates of alpha-synuclein is a hallmark of Parkinson’s and “has been…

FDA weighs in on ketamine for levodopa-induced dyskinesia

PharmaTher Holdings has received guidance from the U.S. Food and Drug Administration (FDA) on the late-stage clinical development of ketamine for levodopa-induced dyskinesia, or uncontrolled movements, in people with Parkinson’s disease. “We are satisfied with the feedback we received from the Type C meeting with the FDA, which lays…

NLY01 fails to slow motor symptom progression in Phase 2 trial

A Phase 2 clinical trial of Neuraly’s NLY01 failed to show the experimental therapy was superior to a placebo at significantly slowing motor symptom progression in adults with early and untreated Parkinson’s disease. Some promising trends among patients younger than 60 were seen following analyses of the trial’s…

FDA clears NeuroRPM, Apple Watch app to monitor daily symptoms

NeuroRPM, an artificial intelligence (AI)-powered app designed to continuously monitor hallmark symptoms of Parkinson’s disease has been cleared for use by the U.S. Food and Drug Administration (FDA). “The clearance of NeuroRPM is a major milestone in the fight against Parkinson’s disease,” Alexander Ksendzovsky, MD, PhD, cofounder and chief…

A dose of ‘hopamine’ may help personalize Parkinson’s care

While dopamine-replacing therapies are a key component of Parkinson’s disease care, they only reflect a person’s physical characteristics or the state of their disease. Adding a dose of “hopamine” — a person’s own unique set of hopes, desires, experiences, and skills — to Parkinson’s care takes patients’ personal characteristics…

Red/yellow brain pigment linked to Parkinson’s disease: Study

People with Parkinson’s disease have higher than normal levels of a nerve cell-damaging red/yellow pigment called pheomelanin in their substantia nigra, the area of the brain that’s mainly affected by the neurodegenerative disease, a study showed. By contrast, levels of eumelanin — an antioxidant black/brown pigment responsible for the…